Aprepitant

• Antiemetics
• ATC:A04AD12

• Aprepitant [Usan]
• Emend

No information avaliable

C₂₃H₂₁F₇N₄O₃

http://www.rxlist.com/cgi/generic3/emend.htm

Aprepitant FDA

534.427 g/mol

No information avaliable

Prácticamente insoluble

Solid

5.535

Cápsula

Para la prevención de náuseas y vómitos asociados con quimioterapia oncológica altamente emetógena, incluso dosis altas de cisplatino (en combinación con otros agentes antieméticos).

Aprepitant, un antiemético, es una sustancia P / neurocinina 1 (NK1) antagonista de los receptores que, en combinación con otros agentes antieméticos, está indicado para la prevención de las náuseas agudas y retrasadas y vómitos asociados con cursos iniciales y repetidos de quimioterapia contra el cáncer altamente emetógena. Aprepitant es un inhibidor selectivo de alta afinidad de los antagonistas de la sustancia humana P / neurocinina 1 (NK1). Aprepitant se ha poca o ninguna afinidad por los receptores serotoninérgicos (5-HT3), la dopamina y los receptores de corticosteroides, los objetivos de las terapias existentes para la quimioterapia, náuseas y vómitos inducidos (CI NV).

No hay información disponible

Physicians should instruct their patients to read the patient package insert before starting therapy with EMEND and to reread it each time the prescription is renewed.

Patients should be instructed to take EMEND only as prescribed. Patients should be advised to take their first dose (125 mg) of EMEND 1 hour prior to chemotherapy treatment.

EMEND may interact with some drugs including chemotherapy; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products.

Patients on chronic warfarin therapy should be instructed to have their clotting status closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle.

Administration of EMEND may reduce the efficacy of hormonal contraceptives. Patients should be advised to use alternative or back-up methods of contraception during treatment with EMEND and for 1 month following the last dose of EMEND.

Humanos y otros mamíferos